- Nevro Announces Director Appointment
- Nevro to Present at Baird 2021 Global Healthcare Conference
- Supermoon Capital Launches with World's First Fund Focused on Sleep
- Nevro to Present at Morgan Stanley 19th Annual Global Healthcare Conference
- Nevro to Present at Wells Fargo Virtual Healthcare Conference
- Nevro Reports Second Quarter 2021 Financial Results and Provides Third Quarter of 2021 Guidance
- Nevro Announces FDA Approval of its 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy (PDN)
- Nevro to Report Second Quarter 2021 Financial Results
- Nevro Announces SENZA-NSRBP Clinical Data Presentation at the American Society of Interventional Pain Physicians 23rd Annual Meeting
- Nevro Announces SENZA-PDN Clinical Data Presentation at the American Diabetes Association 81st Scientific Sessions
Nevro Corp (NVRO:NYQ) closed at 125.45, 26.03% above the 52 week low of 99.54 set on Aug 16, 2021.
99.54Aug 16 2021188.14Dec 23 2020
Markit short selling activity
|Market cap||4.29bn USD|
|EPS (TTM)||-1.97 |
Data delayed at least 15 minutes, as of Sep 16 2021 21:10 BST.